INNT
TOTAL INVALIDATION PROCESSED BY THE IB
02/19/2026
Back to search
Official data from USPTO
IMRELIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
IMRELIX
ST13
US500000079209728Class
5, 42, 44
Filing
79209728
Registration
5450609
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
02/20/2026
Trademark type
Word
Nice classes
5, 42, 44
Filing date
03/23/2017
Registration date
04/24/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/08/2024
Last transaction
02/20/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
SE
Examiner
TIERNEY, MARGERY
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
ISR Immune System Regulation Holding AB
Immune System Regulation Holding AB
Representatives
Chas. Hude A/S
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationspharmaceutical preparations for the treatment and prevention of viral and infectious diseases and pharmaceutical preparations for the treatment of immune dysfunction and pharmaceutical preparations for the treatment of human immunodeficiency virus
Class 42
Scientific research within the medicalpharmaceutical and bacteriological areaSynthetic chemistry and generation of new chemical entities based on molecular structures of macrolides and of GnRH molecules to identify specific lead drug candidates for infectious diseases. Toxicology studies and preparation of investigational new drugs (INDs) according to good laboratory practice (GLP) standard operating proceduresanalysis of pharmacokinetics and metabolism of drugs and new chemical entitiespreparation of pharmaceutical formulationshigh-throughput screening of new chemical entities in the field of anti-viral therapeuticsconsultancy and information relating theretoconducting of tests regarding medical applications; packaging designdesigning and development of medical equipmentdesigning pharmaceutical and medical preparationspreparation of pharmaceutical formulationsdesign and development of granulation technology and tablet technology namelyselection of lead drug candidates in the field of anti-viral therapeutics based on specific molecular structuresdesign of pharmaceutical and medical preparations through analysis of pharmacokinetics and metbolism of drugs and new chemical entitiesmanufacturing of pharmaceutical formulations according to good manufacturing practice (GMP) standard operating proceduresconsultancy and information relating thereto
Class 44
Information and advice relating to pharmaceutical preparationsdiseases and medical conditions and treatmentinformation and advice on-line via computer networks or the Internet and providing information relating to preventiondiagnosis and treatment of infectious diseases and information and advice relating to diagnosis and treatment of diseases and medical disorders
Publications
History of USPTO decisions and trademark events.
30 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
12/30/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
12/30/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/21/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
07/08/2025
C71T
CANCELLED SECTION 71
11/08/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/18/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/28/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
01/24/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/31/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/06/2018
FIMP
FINAL DISPOSITION PROCESSED
08/06/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/24/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
04/24/2018
PUBO
PUBLISHED FOR OPPOSITION
02/06/2018
NPUB
NOTICE OF PUBLICATION
01/17/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/28/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/22/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/22/2017
ALIE
ASSIGNED TO LIE
12/20/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/13/2017
RFNT
REFUSAL PROCESSED BY IB
07/14/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/29/2017
RFRR
REFUSAL PROCESSED BY MPU
06/29/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/20/2017
CNRT
NON-FINAL ACTION WRITTEN
06/19/2017
MAFR
APPLICATION FILING RECEIPT MAILED
06/17/2017
DOCK
ASSIGNED TO EXAMINER
06/15/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/13/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/08/2017
Continuous trademark protection
Get notified about every new filing that threatens IMRELIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.